Key result
ADA/EASD consensus recommends reassessing diabetes therapy every 3–6 months to prevent clinical inertia.
Answers are grounded in this paper and cite their sources.
Consensus report demonstrates the benefits of early glycemic control in diabetes, highlighting recommendations to avoid clinical inertia through treatment reviews every three to six months.
Good outcomes are obtained with early glycemic control, as shown by the UK Prospective Diabetes Study (UKPDS), but the legacy benefits continue ten years after the study ending, and are also present for lipid and blood pressure management. The ADA and EASD consensus report now has, for the first time, evidence-based recommendations: among them, on a blue circle on the top of the flowchart, it is recommended to “avoid clinical inertia”, and “to reassess and modify clinical treatment regularly, every 3-6 months”(1).
No takes yet. Share an insight, caveat, or question.
Kamlesh Khunti (2022) conducted a review in Diabetes. Regular clinical treatment reassessment and modification was evaluated. The ADA and EASD consensus report recommends reassessing and modifying diabetes treatment every 3-6 months to avoid clinical inertia, building on 10-year legacy benefits of early glycemic control.
Synapse has enriched 10 related papers. Consider them for comparative context: